Episode Details

In this episode, Prof. Friedemann Paul from Charité – Universitätsmedizin Berlin, Germany, explains how the European CLAIMS project aims to improve multiple sclerosis care through AI-assisted decision support. CLAIMS brings together MRI, OCT, blood biomarkers such as neurofilament light chain, clinical data and patient-reported outcomes to support more precise predictions of MS progression.

This episode is supported by the European Charcot Foundation.

We talk about precision medicine, RAW and PIRA progression, trust in AI, clinical validation, access, reimbursement and what it takes to bring such a tool into everyday neurological care. A key message of the episode: AI should support neurologists and shared decision making — not replace them.

You can find the written interview here: https://ms-perspektive.de/172-claims/

• What CLAIMS aims to achieve for people with MS
• Why precision medicine matters in multiple sclerosis
• How MRI, OCT, biomarkers and patient-reported outcomes can be integrated
• RAW and PIRA progression explained
• Why AI will not replace neurologists
• How trust, transparency and data quality influence AI-supported care
• Validation, approval, reimbursement and implementation in daily practice
• How people with MS and clinicians can stay updated or get involved

• CLAIMS project: https://www.claims.ms/
• PROCLAIM study: https://www.claims.ms/proclaim/
• European Charcot Foundation – CLAIMS initiative: https://www.charcot-ms.org/initiatives/claims-clinical-impact-through-ai-assisted-ms-care
• RECLAIM study protocol: https://www.frontiersin.org/journals/neurology/articles/10.3389/fneur.2025.1557947/full
• PROCLAIM study: https://clinicaltrials.gov/study/NCT07032246
• icometrix / i